Blood indices and circulating tumor cells for predicting metastasis of hepatocellular carcinoma after liver transplantation

被引:1
作者
Zhuang, Li [1 ]
Liu, Xiang-Yan [1 ]
Zhu, Heng-Kai [1 ]
Wang, Zhuo-Yi [1 ]
Zhang, Wu [1 ]
Jiang, Guo-Ping [1 ]
Zheng, Shu-Sen [1 ]
机构
[1] Zhejiang Shuren Univ, Dept Hepatobiliary & Pancreat Surg, Shulan Hangzhou Hosp, Shulan Int Med Coll, Hangzhou 310015, Peoples R China
关键词
alpha-fetoprotein (AFP); circulating tumor cell; hepatocellular carcinoma; liver transplantation; PIVKA-II; RECURRENCE; MODEL; CIRRHOSIS; CANCER; RISK;
D O I
10.1515/labmed-2021-0019
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Liver transplantation (LT) can benefit the long-term survival of hepatocellular carcinoma (HCC) patients. We hypothesized that circulating tumor cell (CTC) levels and subtypes are intimately associated with metastasis status of HCC patients. This study was designed to test that compositive hematological indices including CTC can provide a prediction of post-LT metastasis. Methods: Between 2017 and 2018, 37 HCC patients within Hangzhou criteria receiving LT were included for analysis. The 24-month follow-up was mainly conducted by outpatient and telephone. Blood samples were collected, and hematological indices were examined. The outcomes such as PFS, recurrence, metastasis, location of recurrence/metastasis, and number of metastases were recorded. Results: The follow-up analysis showed that microvascular invasion (MVI) classification at the baseline is associated with metastasis. Next, alpha-fetoprotein (AFP) level was another useful indicator of postoperative metastasis, especially at the third or fourth month; the protein induced by vitamin K absence or antagonist-II (PIVKA-II) level three months after LT was significantly higher for those who had later metastasis. The mesenchymal CTC level at the 45th day was increased for in the metastasis group. Using twoends Logistic regression, the calculated value MP (metastasis predictor, by above factors). Had an AUC of 0.858 in the ROC curve, with a cutoff value of 0.328. Conclusions: In conclusion, microvascular invasion, AFP level at the third or fourth month, PIVKA-II level at the third month, and mesenchymal CTC level at day 45 were associated with post-LT metastasis. Using Logistic regression based on above variables, the two-year metastasis can be predicted with satisfactory sensitivity and accuracy.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 25 条
[11]   Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies [J].
Matsuda, Yasunobu ;
Ichida, Takafumi ;
Fukumoto, Manabu .
MEDICAL MOLECULAR MORPHOLOGY, 2011, 44 (03) :117-124
[12]   Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma [J].
Merli, M ;
Nicolini, G ;
Gentili, F ;
Novelli, G ;
Iappelli, M ;
Casciaro, G ;
Di Tondo, U ;
Pecorella, I ;
Marasco, A ;
Muda, AO ;
Nudo, F ;
Mennini, G ;
Corradini, SG ;
Riggio, O ;
Berloco, P ;
Attili, AF ;
Rossi, M .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (06) :2535-2540
[13]   High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis [J].
Min, Ae Lyoung ;
Choi, Jong Young ;
Woo, Hyun Young ;
Kim, Jin Dong ;
Kwon, Jung Hyun ;
Bae, Si Hyun ;
Yoon, Seung Kew ;
Shin, Seung Hun ;
Chung, Yeun Jun ;
Jung, Chan Kwon .
CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) :759-767
[14]  
Neuhaus P, 2002, Praxis (Bern 1994), V91, P1396, DOI 10.1024/0369-8394.91.35.1396
[15]   Solitary Muscle Metastasis of Hepatocellular Carcinoma to the Biceps Femoris Muscle with Only Elevated Serum PIVKA-11- A Case Report [J].
Orita, Kazuki ;
Sakamoto, Akio ;
Okamoto, Takeshi ;
Matsuda, Shuichi .
AMERICAN JOURNAL OF CASE REPORTS, 2019, 20 :306-309
[16]  
Reyes JD, 2000, J PEDIATR-US, V136, P795, DOI 10.1016/S0022-3476(00)44469-0
[17]   Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation: Accuracy of the Alpha-Fetoprotein Model in a Single-Center Experience [J].
Varona, M. A. ;
Soriano, A. ;
Aguirre-Jaime, A. ;
Garrido, S. ;
Oton, E. ;
Diaz, D. ;
Portero, J. ;
Bravo, P. ;
Barrera, M. A. ;
Perera, A. .
TRANSPLANTATION PROCEEDINGS, 2015, 47 (01) :84-89
[18]   Long-term results of liver transplantation for hepatocellular carcinoma: An update of the university of Padova experience [J].
Vitale, A. ;
Gringeri, E. ;
Valmasoni, M. ;
D'Amico, F. ;
Carraro, A. ;
Pauletto, A. ;
D'Amico, F. J. ;
Polacco, M. ;
D'Amico, D. F. ;
Cillo, U. .
TRANSPLANTATION PROCEEDINGS, 2007, 39 (06) :1892-1894
[19]   Low recurrence rate of hepatocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression? [J].
Vivarelli, M ;
Bellusci, R ;
Cucchetti, A ;
Cavrini, G ;
De Ruvo, N ;
Aden, AA ;
La Barba, G ;
Brillanti, S ;
Cavallari, A .
TRANSPLANTATION, 2002, 74 (12) :1746-1751
[20]   A Randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation [J].
Xu, Jing ;
Shen, Zhong-Yang ;
Chen, Xin-Guo ;
Zhang, Qing ;
Bian, Hui-Jie ;
Zhu, Ping ;
Xu, Hui-Yun ;
Song, Fei ;
Yang, Xiang-Min ;
Mi, Li ;
Zhao, Qing-Chuan ;
Tian, Rong ;
Feng, Qiang ;
Zhang, Si-He ;
Li, Yu ;
Jiang, Jian-Li ;
Li, Ling ;
Yu, Xiao-Ling ;
Zhang, Zheng ;
Chen, Zhi-Nan .
HEPATOLOGY, 2007, 45 (02) :269-276